The efficacy of Caelyx and hyperthermia for anticancer treatment

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 3, 2007, Pages 246-250

  Kouloulias, Vasilios E ^a   Koukourakis, Georgios V ^a   Petridis, Aristides K ^a   Kouvaris, Ioannis ^a   Gouliamos, Athanasios D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anticancer treatment; Caelyx; Efficacy; Hyperthermia

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOLYTIC INHIBITOR; INTEGRIN; LIGAND; NANOPARTICLE; UNCLASSIFIED DRUG;

ALOPECIA; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RELEASE; ENCAPSULATION; HUMAN; HYPERTHERMIC THERAPY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; ORGAN PERFUSION; OVARY CARCINOMA; PATENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SKIN TOXICITY; SOLID TUMOR; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; NEOPLASMS; PATENTS AS TOPIC;

EID: 36749085315     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207782497208     Document Type: Review

References (68)

1. Overgaard I. The current and potential role of hyperthermia in radiotherapy Int J Radiat Oncol Biol Phys 1989; 16: 535-549.
2. Overgaard J, Bach AJ. Hyperthermia. In Peckman M, Pinedo H, Veronesi. Textbook of Oncology Oxford United Kingdom Oxford University Press. 1995; 823-835.
3. Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer results from 5 randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35: 731-744.
4. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 1994; 54: 987-992.
5. Steart S, Harrington KJ. The biodistribution and pharmacokinetics of Stealth liposomes in patients with solid tumors. Oncology 1997; 11 (Suppl 11): S33-S37.
6. Northfelt D W, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-659.
7. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 1990; 57: 55-64.
8. Brooks BJ, Jr Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986; 4: 200-209.
9. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of Stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000; 39: 207-211.
10. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-3191.
11. Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by Stealth liposomes. Cancer (Phila) 1999; 86: 72-78.
12. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36: 1177-1187.
13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer. Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
14. Goodman, S., Grell, M., Ten, H.T.L.M., Egermont, A.M.M.: WO07082742 ( 2007).
15. WHO. Handbook for Reporting Results of Cancer Treatment. Geneva Switzerland WHO Offset Publications. 1979; 48.
16. Lokich JJ, Moore C. Chemotherapy-associated palmarplantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-799.
17. Chonn A, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995; 6: 698-708.
18. Ning S, Macleod K, Abra R, et al. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumour efficacy. Int J Radiat Oncol Biol Phys 1994; 29: 827-834.
19. van Bree C, Krooshoop JJ, Rietbroek RC, et al. Hyperthermia enhances tumour uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res 1996; 56: 563-568.
20. Gaber MH, Wu NZ, Hong Y, et al. Thermosinsitives liposomes extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36: 1177-1187.
21. Dewhirst MW, Prosnitz L, Thrall D, et al. Hyperthermic treatment of malignant diseases current status and view toward the future Semin Oncol 1997; 24: 616-625.
22. Merlin JL. Encapsulation of doxorubicin in thermosensitive small unilamellar vesicle liposomes Eur J Cancer. 1991; 8: 1026-1030.
23. Kleiter MM, Yu D, Mohammadian LA, et al. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation Clin Cancer Res. 2006; 12(22): 6800-6807.
24. Ponce, AM, Vujaskovic Z, Yuan F, Needham D, Dewhirst MW. Hyperthermia mediated liposomal drug delivery Int J Hyperthermia. 2006; 22(3): 205-213.
25. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation Int J Hyperthermia.2004; 20(7): 781-802.
26. Ben-Yosef R, Gipps M, Zeira M. Hyperthermia and liposomal encapsulated doxorubicin Isr Med Assoc J.2003; 5(6): 407-409.
27. Dvorak J, Zoul Z, Melichar B, et al. Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors J Chemother.2004; 16 Suppl 5: 34-36.
28. Dvor KJ, Zoul Z, Melichar BJ, et al. Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma J Clin Gastroenterol. 2002; 34(1): 96-98.
29. Dvor KJ, Zoul Z, Melichar B, et al. Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: a case report Onkologie. 2001; 24(2): 166-168.
30. Vasilios EK, Costas ED, John RK, et al. Liposomal doxorubicin in conjuction with reirradiation and local hyperthermia treatment in recurrent breast cancer A Phase I/II. Trial Clin Cancer Res 2002; 8: 374-382.
31. Koshiba, K.: EP1803454 (2007).
32. Guiot C, Madon E, Allegro D, Pianta, PG, Baiotto B, Gabriele P. Perfusion and thermal field during hyperthermia Experimental measurements and modeling in recurrent breast cancer Phys Med Biol. 1998; 43: 2831-2843.
33. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft 381 Clinical Cancer Research Cancer Res. 1994; 54: 3352-3356.
34. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy Microvasc Res. 1993; 46: 231-253.
35. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor fissuc Cancer Res 1993; 53: 3765-3770.
36. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene Am J Pathol.1993; 143: 10-14.
37. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease Radiother Oncol. 1984; 2: 343-366.
38. 21-induced fusion and destabilization of liposomes. Biochemistry 1985; 24: 3099-3106.
39. Lee RJ, Wang S, Turk MJ, Low, PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery Biosci Rep. 1998; 18: 69-78.
40. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature Cancer Res 2001; 61: 3027-3032.
41. Gaber MH. Effect of bovine serum on the phase transition temperature of cholestcrol-containing liposomes J Microencapsul.1998; 15: 207-214.
42. Muller-Klieser W, Vaupel P. Effect of hyperthermia on tumor blood flow Biorheology. 1984; 21: 529-538.
43. Song C W, Shakil A, Osborn JL, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures Int J Hyperthermia. 1996; 12: 367-373.
44. Schorcht J. Hyperthermia in tumor therapy Radiobiol Radiother.1990; 31: 383-390.
45. Sakayama K, Masuno H, Miyazaki T, Okumura H, Shibata T, Okuda H. Existence of lipoprotein lipase in human sarcomas and carcinomas Jpn J Cancer Res.1994; 85: 515-521.
46. Cobbs CS, Brenman JE, Aldape KD, Bredt DS., Israel MA. Expression of nitric oxide synthase in human central nervous system tumors Cancer Res. 1995; 55: 727-730.
47. Martin FJ. Pegylated liposomad doxorubicin: scientific rationale and preclinical pharmacology. Oncology. 1997; 11 (Suppl. 11): S11-S20.
48. Storm G, Steerenberg PA, Emmen F, van Borssum WM, Crommelin DJ. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes Biochem Biophys Acta 1998; 965: 136-145.
49. Steel G. Gordon introduction the significance of radiobiology for radiotherapy In G. Steel (ed.) Basic Clinical Radiobiology London Arnold.1997; 01-07.
50. Fukumma D, Yuan F, Endo M, Jain RK Role of nitric oxide in tumor microcirculation Blood flow vascular permeability and leukocyte-endothelial interactions Am J Pathol.1997; 150: 713-725.
51. Ibuki Y, Goto R. Enhancement of NO production from resident peritoneal macrophages by in vitro -irradiation and its relationship to reactive oxygen intermediates Free Radic Biol Med. 1997; 22: 1029-1035.
52. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyelhylene glycol-derivatized phospholipid pharmacokinetic studies in rodents and dogs Pharm Res. 1993; 10: 703-708.
53. Lasic DD, Martin FJ, Gabizon A, Huang SY, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim Biophys Acta. 1991; 1070: 187-192.
54. Lasic, DD. Doxorubicin in sterically stabilized liposomes Nature (Lond.). 1996; 380: 561-562.
55. Lampidis, T.J., Priebe, W.: US2007077160865 (2007).
56. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JS. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery Clin Cancer Res.2000; 6: 2528-2537.
57. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer J Clin Oncol.1999; 17: 3512-3521.
58. Khalifa A, Dodds D, Rampling R, Paterson J, Murray T. Liposomal distribution in malignant glioma possibilities for therapy Nucl Med Commun.1997; 18: 17-23.
59. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J Clin Pharmacol. 1996 36: 55-63.
60. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma Drugs. 1997; 53: 520-538.
61. Stewart S, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors Oncology 1997; 11 (Suppl. 11): S33-S37.
62. Ovegaard J, Nielsen OS. The importance of thermotolerance for the clinical treatment with hyperthermia Radiother Oncol. 1983; 1: 167-178.
63. Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes Cancer Res. 1994; 54: 2186-2191.
64. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia 1999; 15: 345-370.
65. Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer Ann Oncol 1999; 10: 1113-1116.
66. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers Drugs 1997; 54 (Suppl. 4): S22-S29.
67. Engin K, Leeper DB, Tupchong L, Waterman FM. Thermoradiotherapy in the management of superficial malignant tumors. Liposomal Doxorubicin Plus Thermo-Radiotherapy Clin Cancer Res. 1995; 1: 139-145.
68. Xiang, X.D., Wang, G., Yang, H., Melman, J., Dionne, G.G.: WO07061843 (2007).